Deals

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC
AstraZenecaDizal Pharmaceutical

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192) announced that it has received a US$600 million upfront payment from AstraZeneca plc (NYSE: AZN), stemming from the global exclusive licensing agreement for…

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline
ConjuStarFinance

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline

AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology
AbbVieNeomorph

AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology

Ascentage Pharma Prices US IPO at USD 17.25 per ADS
Ascentage PharmaHKG: 6855

Ascentage Pharma Prices US IPO at USD 17.25 per ADS

Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease
Chronic diseaseIMMvention Therapeutix

Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease

Show More